It is a research-only package containing five lyophilized vials labeled 50mg per vial for qualified laboratory and analytical use
Now, the first generic liraglutide has just launched in the US, and it opens a lower-cost option for patients who need proven treatments
Topical ALA, on the other hand, shows some potential results
There are a handful of eligibility requirements for people interested in receiving GLP-1s under the Bridge rollout
Adding to the competitive landscape, Kailera Therapeutics and Hengrui Pharma reported positive topline data from a Phase 2 study of oral ribupatide, a GLP-1/GIP dual agonist, showing approximately 12% mean weight loss at 26 weeks compared to 2.3% for placebo
(Our partner physicians specialize in cancer treatment and prevention